









Markets
/
Stocks
/
nasdaq-ngne
/

Neurogene Inc

NGNE

26.750USD

+0.090+0.34%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

381.70MMarket Cap

LossP/E TTM



Neurogene Inc

26.750

+0.090+0.34%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neurogene Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neurogene Inc's Score

Industry at a Glance

Industry Ranking

61 / 407

Overall Ranking

176 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

57.750

Target Price

+115.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neurogene Inc Highlights

StrengthsRisks

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 925.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 925.00K.

Undervalued

The company’s latest PE is -6.21, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.75M shares, decreasing 17.15% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 542.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.48.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 5.49, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.49

Change



Financials

3.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.78

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Neurogene Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.41, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.21, which is -983.51% below the recent high of 54.85 and -189.52% above the recent low of -17.97.

Score

Industry at a Glance

Previous score

7.41

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Neurogene Inc is 57.50, with a high of 70.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

57.750

Target Price

+115.89%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Neurogene Inc

NGNE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.95, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 34.70 and the support level at 21.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.81

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-2.032

Neutral

RSI(14)

45.484

Neutral

STOCH(KDJ)(9,3,3)

25.114

Sell

ATR(14)

3.576

High Vlolatility

CCI(14)

-178.568

Sell

Williams %R

75.563

Sell

TRIX(12,20)

0.944

Sell

StochRSI(14)

1.892

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

28.798

Sell

MA10

30.714

Sell

MA20

31.121

Sell

MA50

24.433

Buy

MA100

22.382

Buy

MA200

19.243

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 110.33%, representing a quarter-over-quarter decrease of 11.82%. The largest institutional shareholder is The Vanguard, holding a total of 610.34K shares, representing 4.28% of shares outstanding, with 11.84% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Samsara BioCapital, LLC

1.72M

RTW Investments L.P.

1.36M

+1.02%

Casdin Capital, LLC

1.30M

Redmile Group, LLC

1.28M

-2.40%

EcoR1 Capital, LLC

1.27M

McMinn (Rachel L. Ph.D.)

1.25M

-5.41%

Baker Bros. Advisors LP

991.69K

-33.27%

BlackRock Institutional Trust Company, N.A.

820.54K

-13.29%

TD Securities, Inc.

681.34K

+184.77%

The Vanguard Group, Inc.

Star Investors

610.34K

-1.23%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.81, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.